Q32 Bio, Inc. (QTTB)
7.52
-0.25
(-3.22%)
USD |
NASDAQ |
Oct 16, 16:00
7.51
-0.01
(-0.13%)
After-Hours: 20:00
Q32 Bio Research and Development Expense (Annual) : 19.16M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 19.16M |
| December 31, 2024 | 48.14M |
| December 31, 2023 | 31.73M |
| December 31, 2022 | 98.35M |
| December 31, 2021 | 93.08M |
| Date | Value |
|---|---|
| December 31, 2020 | 100.39M |
| December 31, 2019 | 89.40M |
| December 31, 2018 | 47.95M |
| December 31, 2017 | 21.38M |
| December 31, 2016 | 5.695M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Intellia Therapeutics, Inc. | 379.09M |
| Beam Therapeutics, Inc. | 409.62M |
| Prime Medicine, Inc. | 160.64M |
| Prelude Therapeutics, Inc. | 94.30M |
| Twist Bioscience Corp. | 80.28M |